JP6913459B2 - オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー - Google Patents

オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー Download PDF

Info

Publication number
JP6913459B2
JP6913459B2 JP2016531859A JP2016531859A JP6913459B2 JP 6913459 B2 JP6913459 B2 JP 6913459B2 JP 2016531859 A JP2016531859 A JP 2016531859A JP 2016531859 A JP2016531859 A JP 2016531859A JP 6913459 B2 JP6913459 B2 JP 6913459B2
Authority
JP
Japan
Prior art keywords
cto
signature
pathway
response
pharmacodynamic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016531859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526908A5 (https=
JP2016526908A (ja
Inventor
ラシダ エイ カルマリ
ラシダ エイ カルマリ
Original Assignee
タクティカル セラピューティクス インコーポレイテッド
タクティカル セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by タクティカル セラピューティクス インコーポレイテッド, タクティカル セラピューティクス インコーポレイテッド filed Critical タクティカル セラピューティクス インコーポレイテッド
Publication of JP2016526908A publication Critical patent/JP2016526908A/ja
Publication of JP2016526908A5 publication Critical patent/JP2016526908A5/ja
Application granted granted Critical
Publication of JP6913459B2 publication Critical patent/JP6913459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2016531859A 2013-08-02 2014-07-30 オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー Active JP6913459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/957,720 2013-08-02
US13/957,720 US10378059B2 (en) 2013-08-02 2013-08-02 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate
PCT/US2014/048905 WO2015017545A1 (en) 2013-08-02 2014-07-30 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate

Publications (3)

Publication Number Publication Date
JP2016526908A JP2016526908A (ja) 2016-09-08
JP2016526908A5 JP2016526908A5 (https=) 2019-02-14
JP6913459B2 true JP6913459B2 (ja) 2021-08-04

Family

ID=52428197

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016531859A Active JP6913459B2 (ja) 2013-08-02 2014-07-30 オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー

Country Status (9)

Country Link
US (1) US10378059B2 (https=)
EP (1) EP3027776B1 (https=)
JP (1) JP6913459B2 (https=)
KR (1) KR102389934B1 (https=)
CN (1) CN105531380B (https=)
AU (1) AU2014296212B2 (https=)
CA (1) CA2919690C (https=)
IL (1) IL243894B (https=)
WO (1) WO2015017545A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10882841B2 (en) 2016-03-01 2021-01-05 University Of Maryland, Baltimore Wnt signaling pathway inhibitors for treatments of disease
JP6889009B2 (ja) * 2017-04-13 2021-06-18 浜松ホトニクス株式会社 画像取得システム及び画像取得方法
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69633566T2 (de) * 1995-07-21 2005-12-08 Savvipharm Inc. Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
US20030170720A1 (en) * 2001-01-23 2003-09-11 Van Der Kuyl Antoinette Cornelia Means and methods for treatment evaluation
US8137910B2 (en) 2002-05-03 2012-03-20 Duke University Method of regulating gene expression
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
JP2010522567A (ja) 2007-03-28 2010-07-08 メダレックス インコーポレーティッド 遺伝子増幅および発現の方法
WO2009120561A2 (en) * 2008-03-22 2009-10-01 Merck & Co., Inc. Methods and gene expression signature for assessing growth factor signaling pathway regulation status
NZ598482A (en) * 2009-09-04 2014-05-30 Tactical Therapeutics Inc Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
WO2012135845A1 (en) * 2011-04-01 2012-10-04 Qiagen Gene expression signature for wnt/b-catenin signaling pathway and use thereof

Also Published As

Publication number Publication date
EP3027776A4 (en) 2017-03-08
CA2919690C (en) 2021-11-02
EP3027776C0 (en) 2024-02-07
WO2015017545A1 (en) 2015-02-05
US20150038349A1 (en) 2015-02-05
EP3027776A1 (en) 2016-06-08
AU2014296212B2 (en) 2020-10-22
KR102389934B1 (ko) 2022-04-21
IL243894B (en) 2020-06-30
US10378059B2 (en) 2019-08-13
JP2016526908A (ja) 2016-09-08
HK1220493A1 (en) 2017-05-05
IL243894A0 (en) 2016-04-21
CN105531380B (zh) 2021-07-13
CA2919690A1 (en) 2015-02-05
EP3027776B1 (en) 2024-02-07
CN105531380A (zh) 2016-04-27
AU2014296212A1 (en) 2016-02-25
KR20160030535A (ko) 2016-03-18

Similar Documents

Publication Publication Date Title
Paccez et al. Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl
Menyhárt et al. Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
Stelloo et al. Androgen receptor profiling predicts prostate cancer outcome
Velma et al. Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells
Tamborini et al. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas
Schulze et al. RELN signaling modulates glioblastoma growth and substrate‐dependent migration
Liu et al. CALM1 promotes progression and dampens chemosensitivity to EGFR inhibitor in esophageal squamous cell carcinoma
Guibert et al. KRAS mutations in lung adenocarcinoma: molecular and epidemiological characteristics, methods for detection, and therapeutic strategy perspectives
Lu et al. Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression
JP2017101072A (ja) ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
Lee et al. CD133 regulates IL-1β signaling and neutrophil recruitment in glioblastoma
Ji et al. HTRA3 is a prognostic biomarker and associated with immune infiltrates in gastric cancer
Yang et al. EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non–small cell lung cancer
Lin et al. Identification of a 6-RBP gene signature for a comprehensive analysis of glioma and ischemic stroke: cognitive impairment and aging-related hypoxic stress
Li et al. BPTF drives gastric cancer resistance to EGFR inhibitor by epigenetically regulating the C‐MYC/PLCG1/Perk Axis
Sun et al. Finding chemical drugs for genetic diseases
Yang et al. Circulating miRNA expression profiling and target prediction in patients receiving dexmedetomidine
JP6913459B2 (ja) オロト酸カルボキシアミドトリアゾール応答における多種多様なシグナリング経路に関する方法及び分子薬力学バイオマーカー
Erkin et al. Integrative analysis for identification of therapeutic targets and prognostic signatures in non-small cell lung cancer
Tufail et al. Wnt3a is a promising target in colorectal cancer
Abu Zaid et al. A phase II study of buparlisib in relapsed or refractory thymomas
Sirek et al. Expression profile of messenger and micro RNAs related to the histaminergic system in patients with five subtypes of breast cancer
Szokol et al. Discovery and biological evaluation of novel dual EGFR/c-Met inhibitors
Liang et al. Exploring the relationship between abnormally high expression of NUP205 and the clinicopathological characteristics, immune microenvironment, and prognostic value of lower-grade glioma
Yuan et al. Identification of USP39 as a prognostic and predictive biomarker for determining the response to immunotherapy in pancreatic cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181025

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20181227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190912

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20190912

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20190924

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191024

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20191028

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20191213

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20191223

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200608

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210301

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210525

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210603

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210701

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210712

R150 Certificate of patent or registration of utility model

Ref document number: 6913459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250